Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE) from its SEC filings: 2025 revenue $123.7 million (+64% vs the year before), net margin -31%, free cash flow -$27.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $123.7 million |
| Revenue growth | +64% |
| Net income | -$38.6 million |
| Net margin | -31.2% |
| Free cash flow | -$27.5 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -61% |
| Cash | $90.1 million |
| Share count, 1 year | +38% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.